What is the history of Hereditary Neuropathy With Liability To Pressure Palsies HNPP?

Hereditary Neuropathy with Liability to Pressure Palsies (HNPP) was first clinically characterized in the 1940s and 1950s, but it was not until the 1990s that the genetic cause was identified as a deletion on chromosome 17p11.2. This discovery transformed HNPP from a poorly understood, frequently misdiagnosed condition into a well-defined genetic disorder characterized by recurrent, transient nerve palsies.

When was HNPP first described?

While isolated cases of transient nerve palsies were noted in early 20th-century literature, the condition was formally recognized as a distinct hereditary entity in 1947 by de Jong. Researchers initially struggled to categorize it, often confusing Hereditary Neuropathy with Liability to Pressure Palsies (HNPP) with other peripheral neuropathies or traumatic injuries. It wasn't until the 1960s and 70s that family studies confirmed the condition followed an autosomal dominant pattern of inheritance.

How did genetics change our understanding of HNPP?

The most significant milestone in the history of Hereditary Neuropathy with Liability to Pressure Palsies (HNPP) occurred in 1993. Scientists identified that the disorder is caused by a 1.5 megabase deletion involving the PMP22 gene on chromosome 17. This crucial finding allowed for definitive molecular diagnosis, ending years of diagnostic uncertainty for many families who previously endured invasive nerve biopsies to confirm the condition.

What historical misconceptions existed about HNPP?

Before the genetic breakthrough, patients with Hereditary Neuropathy with Liability to Pressure Palsies (HNPP) were often misdiagnosed with chronic nerve compression syndromes, such as carpal tunnel or ulnar neuropathy, without the underlying genetic context being identified. Key historical insights include:

• Misattribution: Early physicians often attributed nerve symptoms solely to physical activity or occupation rather than an underlying genetic susceptibility.


• Diagnostic Shift: The move from relying purely on electrodiagnostic testing (EMG/NCS) to definitive genetic screening improved clinical accuracy.


• Phenotypic Variability: Clinicians learned that the severity of Hereditary Neuropathy with Liability to Pressure Palsies (HNPP) varies significantly even within the same family, correcting the assumption that all patients would present with identical symptoms.

How has patient advocacy evolved?

As our understanding of Hereditary Neuropathy with Liability to Pressure Palsies (HNPP) has grown, so has the patient voice. Today, platforms like DiseaseMaps.org connect the 89 community members who have shared their experiences, fostering a global network that supports research and reduces the isolation historically felt by those diagnosed with this rare condition.

Next steps

• Consult a neurologist or clinical geneticist to discuss genetic testing options for Hereditary Neuropathy with Liability to Pressure Palsies (HNPP).


• Join the DiseaseMaps community to share experiences with others managing this condition.


• Work with an occupational therapist to learn how to modify daily activities to reduce the risk of nerve pressure.

Medical disclaimer: This information is for educational purposes only and should not replace professional medical advice, diagnosis, or treatment.

References

• Orphanet: Hereditary neuropathy with liability to pressure palsies (ORPHA:643)


• NIH GARD: Hereditary Neuropathy with Liability to Pressure Palsies


• OMIM: Neuropathy, Hereditary, with Liability to Pressure Palsies (Entry #162500)


• Neuropathy Commons (Harvard Medical School): HNPP Overview